Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2013

Ibberson Mark, Bron Sylvian, Guex Nicolas, Faes-van't Hull Eveline, Ifticene-Treboux Assia, Henry Luc, Lehr Hans-Anton, Delaloye Jean-François, Coukos George, Xenarios Ioannis, Doucey Marie-Agnès

Abstract excerpt

PURPOSE: Tumor-associated TIE-2-expressing monocytes (TEM) are highly proangiogenic cells critical for tumor vascularization. We previously showed that, in human breast cancer, TIE-2 and VEGFR pathways control proangiogenic activity of TEMs. Here, we examine the contribution of these pathways to immunosuppressive activity of TEMs. EXPERIMENTAL DESIGN: We investigated the changes in immunosuppressive activity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antigen-Presenting Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-2 Antigen

Share to CD11c Antigen

Share to Neovascularization, Pathologic

Share to Receptor, TIE-2

Share to Receptors, Vascular Endothelial Growth Factor

Share to T-Lymphocytes, Regulatory

Source

Identifiers

PMID: 23649001
DOI: 10.1158/1078-0432.CCR-12-3181

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors.PMID 23649001Read ↗

Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches.Semantic proximity Read ↗

Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1RSemantic proximity Read ↗

TREM2 blockade reprograms HER2 CAR macrophages toward inflammatory phagocytes in breast cancer modelsSemantic proximity Read ↗

Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patientsSemantic proximity Read ↗

Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitorsSemantic proximity Read ↗

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine TumorsSemantic proximity Read ↗

Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER– breast cancerSemantic proximity Read ↗

Paracrine signalling in breast cancer: Insights into the tumour endothelial phenotype.Semantic proximity Read ↗

Human breast tumor derived endothelial cells exhibit distinct biological propertiesSemantic proximity Read ↗

Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.Semantic proximity Read ↗

Interleukin-6–mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumorsSemantic proximity Read ↗

Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.